US Biomarkers Market size and share is currently valued at USD 25.92 billion in 2024 and is anticipated to generate an estimated revenue of USD 106.03 Billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 15.16% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

Market’s Growth Drivers
Several interlinked factors are driving the growth of the biomarkers sector in the United States:

1. Increasing Prevalence of Chronic and Complex Diseases
   The U.S. continues to face high incidence of cancers, cardiovascular diseases, neurological diseases (such as Alzheimer’s), and immunological disorders. Biomarkers play an increasingly critical role in early detection, diagnosis, monitoring therapeutic response and prognostication.
   For example, estimates for 2025 suggest over 2 041 910 new cancer cases in the U.S., reinforcing demand for biomarker‑driven oncology diagnostics and companion therapies. 
2. Growth of Precision Medicine and Companion Diagnostics
   As therapies become more targeted and personalized, biomarkers are essential for stratifying patients, predicting response, monitoring minimal residual disease and tailoring treatment regimens. For instance, the U.S. personalized‑medicine biomarkers market was valued at around US$ 9.85 billion in 2024 and is projected to reach roughly US$ 21.67 billion by 2030 (CAGR ~14 %). 
3. Technological Advancements in Genomics, Proteomics, Metabolomics
   Advances in next‑generation sequencing (NGS), high‑throughput proteomics, metabolomic profiling and bioinformatics have improved biomarker discovery, validation and commercialization. The genomics research area dominates within the U.S. biomarkers space, supported by widespread adoption of gene panels and molecular diagnostics. 
4. Strong Regulatory & Institutional Environment
   The U.S. regulatory framework, including initiatives such as the Precision Medicine Initiative and the U.S. Food & Drug Administration’s Fit‑For‑Purpose (FFP) drug development tools, alongside well‑funded academic institutions, make the U.S. a leading environment for biomarker R&D and adoption.
5. Rising Healthcare Expenditure & Investment in Diagnostics
   With increases in healthcare spending and demand for advanced diagnostics, laboratories, biobanking facilities, and biotech companies are investing heavily in biomarker testing, implementation and commercialization across the U.S.

Key Trends
Several overarching trends are shaping the U.S. biomarkers market, influencing how the market evolves and where investment is heading:

1. Expansion of Non‑Invasive & Liquid Biopsy Biomarkers
   Blood‑based biomarkers, cell‑free DNA, circulating tumor DNA (ctDNA), and minimal residual disease (MRD) testing are rapidly gaining traction. For example, the U.S. blood‑based biomarkers market was valued at USD 3.0499 billion in 2024 and expected to grow to USD 4.393 billion by 2030 (CAGR ~6.8 %). 
2. Growth in Neurological and Rare Disease Biomarkers
   While oncology remains the dominant indication, neurological disorders (e.g., Alzheimer’s, Parkinson’s) are emerging as high‑growth areas. The U.S. biomarkers market research indicated the neurological disorders segment will witness the fastest CAGR during forecast years. 
3. Integration with Artificial Intelligence (AI), Big Data & Predictive Analytics
   AI and machine learning are increasingly used to analyze biomarker data, detect patterns, predict outcomes and optimize diagnostics. These technologies enable improved accuracy, better stratification and faster validation of biomarker candidates.
4. Shift Toward Preventive and Predictive Healthcare Models
   With emphasis on value‑based care and early intervention, biomarkers are being used not just for treatment decisions but also risk‑assessment, screening and preventive health monitoring. The U.S. predictive biomarkers market was valued at USD 9.5329 billion in 2024 and is projected to reach USD 24.363 billion by 2030 (CAGR ~17.6 %). 
5. Rise of Companion Diagnostics & Biomarker‑Guided Therapies
   Many new drug approvals in oncology and immunology now require biomarker testing (e.g., PD‑L1, BRCA, HER2). This has increased demand for diagnostics platforms tied to specific therapies and has established biomarkers as a strategic asset within pharmaceutical pipelines.

Research Scope
The research scope within the U.S. biomarkers market includes multiple dimensions: discovery, validation, commercialization, regulatory pathways, and application expansion. Some key research areas include:

• Discovery and Validation of Novel Biomarkers: Investigations into genomics, proteomics, metabolomics and epigenetics to identify new markers for disease initiation, progression or therapeutic response.
• Technology Innovation: Enhancing assay sensitivity, multiplexing, automation, sample throughput, point‑of‑care diagnostics, and non‑invasive collection methods (e.g., liquid biopsies, saliva, tissue‑free biomarkers).
• Clinical Utility & Real‑World Evidence: Demonstrating clinical validity and utility of biomarkers across indications, including in large‑scale cohorts, biobanks and longitudinal monitoring.
• Regulatory & Reimbursement Strategy: Navigating FDA pathways, ensuring analytic and clinical validation, aligning biomarker diagnostics with reimbursement frameworks, and establishing standardized protocols.
• Market Adoption & Implementation Research: Understanding barriers to adoption (e.g., cost, workflow integration, clinician education), optimizing laboratory infrastructure, and scaling biomarker usage in routine care.
• Cross‑discipline & Multi‑Modal Omics Integration: Combining biomarker data with imaging, digital health tools, wearable devices and AI analytics to enable holistic patient monitoring and personalized treatment strategies.